Stock Ratings / Health Care / PBLS / financials

ACAD (66) AMLX (38) OGN (61) VKTX (44) ⌘ Pro Terminal →

Parabilis Medicines Inc. (PBLS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$28.70 +1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Parabilis Medicines Inc. (PBLS) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $3.50B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBLS)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PBLS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$98.0M (2.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	$0	$0	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBLS)

✓Walkthrough of PBLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.18%📐 HORIZONTAL RANGE

2026-10-30O $28.59H $28.74L $27.48C $28.70VOL 814.0K

RES: $43.99SUP: $22.44SMA50: $32.96SMA200: $32.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBLS Butterfly Map → + Track PBLS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBLS)

Health Care Rank #201 of 1016 ⚔️ ACAD vs PBLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBLS vs. ACAD, AMLX, OGN, VKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Parabilis Medicines Inc. (PBLS) ranks #201 by composite RQD confidence (60/100, grade C-) and #194 by equity capitalization ($3.50B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. ACAD currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with PBLS at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBLS ACTIVE Parabilis Medicines Inc.	C-	60/100	—	—	—	+1.88%	$3.50B	Benchmark Subject
ACAD ACADIA Pharmaceuticals Inc.	C+	66/100	9.1x	91.7%	7.9%	+2.17%	$3.58B	/acad-vs-pbls →
AMLX Amylyx Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	+2.17%	$3.60B	/amlx-vs-pbls →
OGN Organon & Co.	C-	61/100	19.4x	53.3%	24.9%	+0.22%	$3.63B	/ogn-vs-pbls →
VKTX Viking Therapeutics Inc.	D	44/100	—	—	-35.0%	+5.92%	$3.38B	/vktx-vs-pbls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001657677

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Parabilis Medicines Inc. (PBLS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PBLS closed FY2025 with $80.8M in total assets against $600.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$80.8M	$600.0K

3. PBLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Parabilis Medicines Inc. (NASDAQ: PBLS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $28.70 (+1.88% 1D, market cap $3.50B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PBLS ranks #201 in composite RQD confidence.

How does PBLS compare to ACAD and AMLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBLS carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a C+ grade (66/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBLS?

Per PBLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001657677), Parabilis Medicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $80.8M in total assets and $600.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBLS trading relative to its 50-day, 200-day, and 52-week technical levels?

PBLS last traded at $28.70 (+1.88% on volume of 844,759 shares), positioning the stock -12.92% below its 50-day simple moving average ($32.96) and -10.92% below its 200-day simple moving average ($32.22). Across its 52-week range of $22.66 to $42.49, PBLS sits at the 30.5% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($25.11 to $32.29).